β-Amyloid dynamics in human plasma

Archives of Neurology

Volumn 69, Issue 12, 2012, Pages 1591-1597

  Huang, Yafei ^a   Potter, Rachel ^a   Sigurdson, Wendy ^a   Kasten, Tom ^a   Connors, Rose ^a   Morris, John C ^a   Benzinger, Tammie ^a   Mintun, Mark ^a,c   Ashwood, Tim ^b   Ferm, Mats ^b   Budd, Samantha L ^b   Bateman, Randall J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42];

ADULT; AGING; AMYLOIDOSIS; ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL;

ADULT; AGED; AGED, 80 AND OVER; AGING; AMYLOID BETA-PEPTIDES; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; PEPTIDE FRAGMENTS; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 84871235613     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2012.18107     Document Type: Article

References (22)

1. Ferri CP, Prince M, Brayne C, et al Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112-2117. (Pubitemid 41797645)
2. Aronson MK, Ooi WL, Geva DL, Masur D, Blau A, Frishman W. Dementia: age-dependent incidence, prevalence, and mortality in the old old. Arch Intern Med. 1991;151(5):989-992.
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353- 356. (Pubitemid 34790756)
4. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38(4):643-648.
5. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55(7):937-945. (Pubitemid 28335112)
6. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512-519. (Pubitemid 43358072)
7. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56(6):673-680. (Pubitemid 29266465)
8. Huang Y, Potter R, Sigurdson W, et al. Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. Arch Neurol. 2012;69(1):51-58.
9. Weldemichael DA, Grossberg GT. Circadian rhythm disturbances in patients with Alzheimer's disease: a review [published online September 2, 2010]. Int J Alzheimers Dis. doi:10.4061/2010/716453.
10. Tranah GJ, Blackwell T, Stone KL, et al SOF Research Group. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol. 2011;70(5):722-732.
11. Yaffe K, Weston A, Graff-Radford NR, et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA. 2011;305(3):261-266.
12. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413.
13. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60(7):958-964. (Pubitemid 36858355)
14. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452. (Pubitemid 44214969)
15. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med. 2009;1(8-9):371-380.
16. Weigand SD, Vemuri P, Wiste HJ, et al Alzheimer's Disease Neuroimaging Initiative. Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid. Alzheimers Dement. 2011;7(2):133-141.
17. Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005-1007.
18. Kang J-E, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A. 2007;104(25):10673-10678. (Pubitemid 47185723)
19. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science. 2010;330(6012):1774.
20. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68(9):666-669. (Pubitemid 46667813)
21. Slats D, Claassen JAHR, Spies PE, et al. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Neurobiol Aging. 2012;33(4):831.
22. Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48(6):913-922. (Pubitemid 41814696)